PCM
HBIO icon

Prelude Capital Management’s Harvard Bioscience HBIO Stock Holding History

Prelude Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,311
Closed -$35.3K – 1342
2024
Q3 		$35.3K Sell
1,311
-712
-35% -$21K ﹤0.01% 1226
2024
Q2 		$57.6K Buy
2,023
+370
+22% +$13K ﹤0.01% 1140
2024
Q1 		$70.1K Hold
1,653
– – ﹤0.01% 1231
2023
Q4 		$88.4K Sell
1,653
-307
-16% -$13.9K 0.01% 1038
2023
Q3 		$84.3K Buy
1,960
+710
+57% +$32.8K 0.01% 1006
2023
Q2 		$68.6K Buy
+1,250
New +$68.6K ﹤0.01% 959
2018
Q1 		– Sell
-190
Closed -$6K – 1596
2017
Q4 		$6K Buy
+190
New +$6.41K ﹤0.01% 1252
2016
Q2 		– Sell
-1,510
Closed -$46K – 1632
2016
Q1 		$46K Buy
1,510
+490
+48% +$13.9K 0.01% 987
2015
Q4 		$35K Buy
1,020
+653
+178% +$22.3K 0.01% 1107
2015
Q3 		$14K Buy
+367
New +$17.1K ﹤0.01% 1296

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Prelude Capital Management's HBIO Position: Q4 2024 in Review

Prelude Capital Management sold out of Harvard Bioscience (HBIO) in Q4 2024, closing a stake of 1,311 shares — an estimated $35.3K sold.

Prelude Capital Management first reported a position in HBIO in Q3 2015 and held it in 10 quarters. The position peaked at $88.4K in Q4 2023. 95 funds tracked by Wall St. Rank hold HBIO as of Q4 2024.

  • Prelude Capital Management reported no remaining Harvard Bioscience position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 1,311 Harvard Bioscience shares in Q4 2024, an estimated $35.3K.
  • Prelude Capital Management first reported a position in Harvard Bioscience in Q3 2015 and held it in 10 quarters.
  • Prelude Capital Management's Harvard Bioscience position peaked at $88.4K in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.